CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CINP (ImmuneEditome ID:51550)

1. Gene summary of enriched editing regions for CINP

check button Gene summary
Gene informationGene symbol

CINP

Gene ID

51550

GeneSynonyms-
GeneCytomap

14q32.31

GeneTypeprotein-coding
GeneDescriptioncyclin-dependent kinase 2-interacting protein|CDK2-interacting protein
GeneModificationdate20230329
UniprotIDQ9BW66;H0YKY0;A0A024R6M9
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr14:102342829-102343527:-ENST00000559514.4ENSG00000100865.13CINPUTR3AluSp,AluSx,AluScchr14:102342829-102343527:-.alignment
chr14:102345517-102348171:-ENST00000560326.1ENSG00000100865.13CINPncRNA_exonicAluSq,(TAT)n,FLAM_A,AluSz,AluSx,AluJr,AluSc,AluJbchr14:102345517-102348171:-.alignment


Top

2. Tumor-specific enriched editing regions for CINP


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr14:102345517-102348171:-BRCAEER6.3525e-03image
ENSG00000100865.13,CINPBRCAEAG1.4702e-03image
chr14:102345517-102348171:-KICHEER3.5147e-02image
ENSG00000100865.13,CINPKICHEAG3.6907e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr14:102345517-102348171:-CESCEER3.3720e-021.7070e-021.0219e+02image
ENSG00000100865.13,CINPCESCEAG2.1472e-021.7070e-021.0219e+02image

Top

3. Enriched editing regions and immune related genes for CINP


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr14:102345517-102348171:-GBMEERENSG00000100564,PIGH-0.47372.3132e-061.1614e-08-0.4358imageNADAR;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBPNAT_cells_gamma_deltaGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr14:102345517-102348171:-GBMEERENSG00000119723,COQ6-0.47042.4598e-064.2527e-09-0.4474imageNADAR;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPL;HNRNPM;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;VIMNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr14:102345517-102348171:-GBMEERENSG00000129472,RAB2B-0.45187.2867e-067.4502e-08-0.4133imageNADAR;CELF2;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;KHDRBS3;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBPNAT_cells_follicular_helperGSVA_HALLMARK_COAGULATION
chr14:102345517-102348171:-GBMEERENSG00000105197,TIMM50-0.44471.1885e-054.5750e-08-0.4194imageNADAR;CELF2;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;LARP7;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBP;VIMTIMM50MonocytesGSVA_HALLMARK_MYC_TARGETS_V1
chr14:102345517-102348171:-GBMEERENSG00000197162,ZNF785-0.43442.2927e-052.5187e-08-0.4267imageNADAR;CELF2;EIF4A3;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;TAF15;TARDBPNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr14:102345517-102348171:-GBMEERENSG00000072042,RDH11-0.42494.2491e-058.5661e-08-0.4116imageNADAR;CELF2;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;KHDRBS3;LARP7;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBP;VIMNAMonocytesGSVA_HALLMARK_MYC_TARGETS_V1
chr14:102345517-102348171:-GBMEERENSG00000131067,GGT7-0.40241.3422e-041.0721e-07-0.4087imageNADAR;CELF2;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;LARP7;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBP;VIMNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr14:102345517-102348171:-GBMEERENSG00000218980,FTH1P150.39502.0418e-041.3442e-090.4601imageNNNAMonocytesGSVA_HALLMARK_MYC_TARGETS_V2
chr14:102345517-102348171:-OVEERENSG00000182774,RPS170.26133.8494e-034.9443e-100.4004imageNADAR;EIF4A3;ELAVL1;FUS;HNRNPA1;HNRNPC;HNRNPK;IGF2BP2;TAF15;TARDBPNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr14:102345517-102348171:-UVMEERENSG00000233754,AP001628.70.41881.8426e-023.2565e-040.4352imageNFBLNAMast_cells_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for CINP


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000100865.13,CINP
GBMEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.40814.9463e-041.7657e-07-0.4059imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;RBM10;RBM27;RBM5;SF3B4;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000100865.13,CINP
GBMEAGESENSG00000077809.8chr774711031:74711109:74714856:74714916:74716893:74716950-0.42023.2070e-041.9127e-07-0.4024imageNNNAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr14:102345517-102348171:-
GBMEERESENSG00000101901.6chrX111736713:111736879:111744667:111744904:111752789:1117528300.33161.6646e-037.5072e-080.4654imageNADAR;CELF2;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;KHDRBS3;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBP;VIMNAMonocytesGSVA_HALLMARK_DNA_REPAIR
ENSG00000100865.13,CINP
GBMEAGESENSG00000101901.6chrX111736713:111736879:111744667:111744904:111752789:1117528300.32332.9203e-031.4499e-070.4562imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;RBM5;SF3B4;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMonocytesGSVA_HALLMARK_DNA_REPAIR
chr14:102345517-102348171:-
GBMEERESENSG00000077809.8chr774711031:74711109:74714856:74714916:74716893:74716950-0.42951.9271e-041.0519e-07-0.4102imageNNNAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr14:102345517-102348171:-
GBMEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.41453.2958e-041.0857e-07-0.4122imageNADAR;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;KHDRBS3;LARP7;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBP;VIMPRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr14:102345517-102348171:-
GBMEERIRENSG00000133858.11chr1271609471:71613435:71614534:71614700-0.29727.4943e-037.3941e-06-0.4027imageNADAR;CELF2;CNBP;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;KHDRBS3;LARP7;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TAF15;TARDBP;VIMNAPlasma_cellsGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000100865.13,CINP
THYMEAGIRENSG00000125648.10chr196440063:6441123:6441978:6442159-0.36864.7448e-031.2753e-05-0.4400imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;SF3B4;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000100865.13,CINP
THYMEAGIRENSG00000146830.9chr7100682589:100682777:100683011:100683218-0.37671.5297e-025.0886e-05-0.4247imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;RBM10;RBM27;SF3B4;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMast_cells_restingGSVA_HALLMARK_P53_PATHWAY
ENSG00000100865.13,CINP
THYMEAGESENSG00000188554.9chr1743190608:43190776:43191371:43191581:43193093:43193253-0.32662.6894e-022.6476e-04-0.4120imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;SF3B4;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NADendritic_cells_restingGSVA_HALLMARK_MYC_TARGETS_V2

More results



Top

5. Enriched editing regions and immune infiltration for CINP


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr14:102345517-102348171:-ACCEERT_cells_gamma_delta4.1341e-030.3621image
ENSG00000100865.13,CINPACCEAGMacrophages_M14.4252e-020.2564image
chr14:102345517-102348171:-BLCAEERT_cells_CD4_naive2.9630e-02-0.1731image
ENSG00000100865.13,CINPBLCAEAGT_cells_CD4_memory_activated4.2120e-020.1594image
chr14:102345517-102348171:-BRCAEERDendritic_cells_activated3.8735e-030.1010image
chr14:102345517-102348171:-CESCEERDendritic_cells_resting3.1711e-02-0.1606image
ENSG00000100865.13,CINPCESCEAGDendritic_cells_resting3.6760e-02-0.1562image
chr14:102345517-102348171:-COADEERDendritic_cells_activated4.0106e-020.1630image
ENSG00000100865.13,CINPCOADEAGDendritic_cells_activated3.7906e-020.1648image
ENSG00000100865.13,CINPESCAEAGT_cells_gamma_delta4.8789e-020.1693image
chr14:102345517-102348171:-GBMEERMacrophages_M01.9252e-03-0.2457image
ENSG00000100865.13,CINPGBMEAGMacrophages_M01.9774e-03-0.2451image
chr14:102345517-102348171:-HNSCEERMacrophages_M21.9231e-040.2251image
ENSG00000100865.13,CINPHNSCEAGMacrophages_M21.4119e-040.2288image
chr14:102345517-102348171:-KICHEERDendritic_cells_activated1.8749e-020.2954image
ENSG00000100865.13,CINPKICHEAGDendritic_cells_activated1.9770e-020.2930image
chr14:102345517-102348171:-KIRCEERMast_cells_resting4.1100e-02-0.1314image
chr14:102345517-102348171:-KIRPEERNK_cells_resting1.1156e-020.1909image
ENSG00000100865.13,CINPKIRPEAGNK_cells_resting1.0576e-020.1912image
chr14:102345517-102348171:-LGGEERNK_cells_activated1.7565e-030.1385image
ENSG00000100865.13,CINPLGGEAGNK_cells_activated1.8719e-030.1377image
chr14:102345517-102348171:-LIHCEERMacrophages_M01.4767e-02-0.2684image
ENSG00000100865.13,CINPLIHCEAGT_cells_CD4_memory_resting2.6602e-020.2391image
chr14:102345517-102348171:-LUADEERB_cells_naive4.0405e-020.1260image
ENSG00000100865.13,CINPLUADEAGB_cells_naive3.8557e-020.1267image
chr14:102345517-102348171:-LUSCEERT_cells_CD4_memory_resting2.2185e-020.1316image
ENSG00000100865.13,CINPLUSCEAGT_cells_CD4_memory_resting4.7597e-020.1135image
chr14:102345517-102348171:-MESOEERT_cells_regulatory_(Tregs)5.1842e-030.4098image
ENSG00000100865.13,CINPMESOEAGT_cells_regulatory_(Tregs)5.1842e-030.4098image
chr14:102345517-102348171:-OVEERB_cells_naive1.7998e-02-0.1580image
ENSG00000100865.13,CINPOVEAGB_cells_naive4.1112e-02-0.1354image
chr14:102345517-102348171:-PCPGEEREosinophils1.6823e-02-0.2040image
ENSG00000100865.13,CINPPCPGEAGEosinophils2.1712e-02-0.1953image
chr14:102345517-102348171:-PRADEERB_cells_naive6.0338e-030.1265image
ENSG00000100865.13,CINPPRADEAGB_cells_naive1.5297e-030.1458image
chr14:102345517-102348171:-READEERDendritic_cells_resting4.3496e-020.2733image
ENSG00000100865.13,CINPREADEAGDendritic_cells_resting4.3329e-020.2735image
chr14:102345517-102348171:-SARCEERT_cells_gamma_delta1.2138e-020.2017image
ENSG00000100865.13,CINPSARCEAGT_cells_gamma_delta1.5008e-020.1938image
chr14:102345517-102348171:-SKCMEERT_cells_CD82.7563e-030.1676image
ENSG00000100865.13,CINPSKCMEAGT_cells_CD88.2507e-030.1477image
chr14:102345517-102348171:-STADEERMacrophages_M23.2802e-02-0.1384image
ENSG00000100865.13,CINPSTADEAGMacrophages_M23.6928e-02-0.1331image
chr14:102345517-102348171:-THYMEERMonocytes2.8144e-020.2265image
ENSG00000100865.13,CINPTHYMEAGMonocytes1.8966e-020.2416image
chr14:102345517-102348171:-UCECEERNK_cells_activated4.3496e-030.2815image
ENSG00000100865.13,CINPUCECEAGNK_cells_activated1.6214e-030.3097image
ENSG00000100865.13,CINPUCSEAGT_cells_gamma_delta2.8604e-020.3600image
chr14:102345517-102348171:-UVMEERT_cells_gamma_delta1.0194e-020.3190image
ENSG00000100865.13,CINPUVMEAGT_cells_gamma_delta1.0308e-020.3185image


Top

6. Enriched editing regions and immune gene sets for CINP


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr14:102345517-102348171:-ACCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.1778e-020.3206image
ENSG00000100865.13,CINPACCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG4.7457e-020.2528image
ENSG00000100865.13,CINPBLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.0873e-020.1990image
chr14:102345517-102348171:-BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.0052e-030.2440image
ENSG00000100865.13,CINPBRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.7757e-040.1215image
chr14:102345517-102348171:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8058e-040.1307image
chr14:102345517-102348171:-CESCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.5955e-02-0.1799image
ENSG00000100865.13,CINPCESCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.6713e-02-0.1787image
chr14:102345517-102348171:-COADGSVA_HALLMARK_HEME_METABOLISMEER3.6998e-04-0.2790image
ENSG00000100865.13,CINPCOADGSVA_HALLMARK_HEME_METABOLISMEAG3.1167e-04-0.2823image
ENSG00000100865.13,CINPDLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.1035e-020.4265image
ENSG00000100865.13,CINPESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.5286e-020.1720image
chr14:102345517-102348171:-GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.1780e-040.3025image
ENSG00000100865.13,CINPGBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.6664e-040.2961image
chr14:102345517-102348171:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.5298e-040.2018image
ENSG00000100865.13,CINPHNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6078e-030.1904image
ENSG00000100865.13,CINPKICHGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.1181e-03-0.3307image
chr14:102345517-102348171:-KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.9755e-03-0.3367image
ENSG00000100865.13,CINPKIRCGSVA_HALLMARK_MYC_TARGETS_V2EAG1.7485e-020.1523image
chr14:102345517-102348171:-KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.4984e-020.1290image
chr14:102345517-102348171:-KIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEER6.0645e-05-0.2975image
ENSG00000100865.13,CINPKIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG5.3668e-05-0.2979image
ENSG00000100865.13,CINPLGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.0876e-04-0.1709image
chr14:102345517-102348171:-LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.4938e-05-0.1800image
ENSG00000100865.13,CINPLIHCGSVA_HALLMARK_UV_RESPONSE_UPEAG7.0645e-03-0.2885image
chr14:102345517-102348171:-LIHCGSVA_HALLMARK_MYC_TARGETS_V2EER4.6834e-03-0.3094image
chr14:102345517-102348171:-LUADGSVA_HALLMARK_HEME_METABOLISMEER7.6327e-03-0.1636image
ENSG00000100865.13,CINPLUADGSVA_HALLMARK_HEME_METABOLISMEAG1.2484e-02-0.1527image
ENSG00000100865.13,CINPOVGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG5.6028e-04-0.2268image
chr14:102345517-102348171:-OVGSVA_HALLMARK_MITOTIC_SPINDLEEER1.4541e-04-0.2511image
ENSG00000100865.13,CINPPAADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG6.4578e-040.3567image
chr14:102345517-102348171:-PAADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER6.4578e-040.3567image
chr14:102345517-102348171:-PRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.9968e-040.1600image
ENSG00000100865.13,CINPPRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.2337e-040.1554image
chr14:102345517-102348171:-SARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER4.9959e-03-0.2251image
ENSG00000100865.13,CINPSARCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG8.9893e-03-0.2079image
ENSG00000100865.13,CINPSKCMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.7772e-02-0.1327image
chr14:102345517-102348171:-SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEER5.4506e-03-0.1558image
ENSG00000100865.13,CINPSTADGSVA_HALLMARK_MYC_TARGETS_V2EAG1.3853e-020.1567image
chr14:102345517-102348171:-STADGSVA_HALLMARK_MYC_TARGETS_V2EER4.4520e-020.1304image
chr14:102345517-102348171:-TGCTGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.6580e-02-0.2534image
ENSG00000100865.13,CINPTGCTGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.6580e-02-0.2534image
ENSG00000100865.13,CINPTHYMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.5651e-020.2301image
chr14:102345517-102348171:-THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1246e-020.2604image
ENSG00000100865.13,CINPUCECGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.4732e-03-0.3124image
chr14:102345517-102348171:-UCECGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.1053e-03-0.3200image


Top

7. Enriched editing regions and drugs for CINP


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000100865.13,CINPACCErlotinibEAG6.8403e-03-0.3401image
chr14:102345517-102348171:-ACCLFM.A13EER2.0640e-030.3870image
chr14:102345517-102348171:-BLCAJNK.Inhibitor.VIIIEER2.5551e-03-0.2384image
ENSG00000100865.13,CINPBLCAJNK.Inhibitor.VIIIEAG2.2796e-03-0.2374image
ENSG00000100865.13,CINPBRCAGW843682XEAG1.3096e-03-0.1118image
chr14:102345517-102348171:-BRCAGW843682XEER9.1456e-04-0.1158image
chr14:102345517-102348171:-CESCGW843682XEER3.0227e-03-0.2205image
ENSG00000100865.13,CINPCESCGW843682XEAG2.9513e-03-0.2210image
chr14:102345517-102348171:-COADBMS.509744EER4.4410e-040.2753image
ENSG00000100865.13,CINPCOADBMS.509744EAG4.3361e-040.2758image
ENSG00000100865.13,CINPDLBCBleomycinEAG9.8786e-03-0.4712image
ENSG00000100865.13,CINPGBMCGP.082996EAG3.4118e-07-0.3936image
chr14:102345517-102348171:-GBMCGP.082996EER1.9683e-07-0.4009image
chr14:102345517-102348171:-HNSCGW843682XEER3.5930e-04-0.2156image
ENSG00000100865.13,CINPHNSCFH535EAG3.5925e-040.2148image
ENSG00000100865.13,CINPKICHBIRB.0796EAG9.9515e-05-0.4706image
chr14:102345517-102348171:-KICHBIRB.0796EER1.6108e-04-0.4579image
chr14:102345517-102348171:-KIRCAZD.2281EER1.3713e-04-0.2427image
ENSG00000100865.13,CINPKIRCAZD.2281EAG1.4997e-04-0.2408image
chr14:102345517-102348171:-KIRPBAY.61.3606EER2.4995e-030.2265image
ENSG00000100865.13,CINPKIRPBAY.61.3606EAG2.6406e-030.2241image
ENSG00000100865.13,CINPLGGA.770041EAG2.2263e-07-0.2276image
chr14:102345517-102348171:-LGGA.770041EER1.5819e-07-0.2303image
chr14:102345517-102348171:-LIHCAZD7762EER5.5551e-040.3731image
ENSG00000100865.13,CINPLIHCAZD7762EAG4.8985e-040.3680image
ENSG00000100865.13,CINPLUADBMS.754807EAG2.0890e-03-0.1875image
chr14:102345517-102348171:-LUADBMS.754807EER2.3831e-03-0.1859image
chr14:102345517-102348171:-LUSCCMKEER4.6079e-03-0.1626image
ENSG00000100865.13,CINPLUSCAZD6244EAG4.9416e-03-0.1606image
chr14:102345517-102348171:-MESOCyclopamineEER9.9885e-03-0.3802image
ENSG00000100865.13,CINPMESOCyclopamineEAG9.9885e-03-0.3802image
ENSG00000100865.13,CINPOVKIN001.135EAG1.0899e-050.2867image
chr14:102345517-102348171:-OVAZD.2281EER4.3977e-06-0.3020image
chr14:102345517-102348171:-PAADBX.795EER1.4463e-030.3345image
ENSG00000100865.13,CINPPAADBX.795EAG1.4463e-030.3345image
ENSG00000100865.13,CINPPRADCisplatinEAG3.3446e-04-0.1648image
chr14:102345517-102348171:-PRADCisplatinEER2.8654e-04-0.1666image
ENSG00000100865.13,CINPREADCEP.701EAG6.4016e-03-0.3633image
chr14:102345517-102348171:-READCEP.701EER5.5519e-03-0.3691image
ENSG00000100865.13,CINPSARCAG.014699EAG6.2474e-040.2701image
chr14:102345517-102348171:-SARCAG.014699EER1.6653e-040.2989image
chr14:102345517-102348171:-SKCMGSK269962AEER3.6424e-02-0.1181image
chr14:102342829-102343527:-STADDMOGEER8.3808e-030.5153image
ENSG00000100865.13,CINPSTADAP.24534EAG1.4771e-040.2396image
chr14:102345517-102348171:-STADEmbelinEER1.0669e-030.2108image
chr14:102345517-102348171:-THCAABT.263EER2.8716e-030.1415image
ENSG00000100865.13,CINPTHCAABT.263EAG9.4355e-030.1228image
ENSG00000100865.13,CINPTHYMGSK.650394EAG1.0815e-02-0.2618image
chr14:102345517-102348171:-THYMBMS.708163EER1.1473e-020.2597image
ENSG00000100865.13,CINPUCECFH535EAG3.6236e-040.3480image
chr14:102345517-102348171:-UCECFH535EER7.3925e-050.3839image
ENSG00000100865.13,CINPUCSKU.55933EAG3.5566e-020.3466image
chr14:102345517-102348171:-UCSCMKEER1.2722e-02-0.4112image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType